US 10,376,579 B2
Nanoparticle complexes of albumin, paclitaxel, and anti-VEGF antibody for treatment of cancer
Svetomir N. Markovic, Rochester, MN (US); and Wendy K. Nevala, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Feb. 24, 2016, as Appl. No. 15/52,336.
Application 15/052,336 is a continuation of application No. 14/432,979, previously published as PCT/US2013/062638, filed on Sep. 30, 2013.
Claims priority of provisional application 61/725,293, filed on Nov. 12, 2012.
Claims priority of provisional application 61/708,575, filed on Oct. 1, 2012.
Prior Publication US 2016/0256431 A1, Sep. 8, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/32 (2006.01); A61K 39/395 (2006.01); A61K 31/337 (2006.01); C07K 16/22 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); C07K 16/30 (2006.01); A61K 47/69 (2017.01); A61K 47/68 (2017.01); A61K 31/282 (2006.01); A61K 47/64 (2017.01); A61K 45/06 (2006.01); B82Y 5/00 (2011.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 33/24 (2019.01); A61K 31/555 (2006.01); A61K 41/00 (2006.01); A61K 9/14 (2006.01)
CPC A61K 39/39558 (2013.01) [A61K 9/0019 (2013.01); A61K 9/51 (2013.01); A61K 9/5169 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 39/395 (2013.01); A61K 47/643 (2017.08); A61K 47/6801 (2017.08); A61K 47/6803 (2017.08); A61K 47/6845 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); A61K 47/6929 (2017.08); A61K 47/6931 (2017.08); C07K 16/22 (2013.01); C07K 16/3015 (2013.01); A61K 9/14 (2013.01); A61K 31/555 (2013.01); A61K 33/24 (2013.01); A61K 41/0052 (2013.01); A61K 45/06 (2013.01); A61K 47/6849 (2017.08); A61K 47/6863 (2017.08); A61K 47/6865 (2017.08); A61K 47/6867 (2017.08); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 2039/6056 (2013.01); B82Y 5/00 (2013.01); C07K 16/2887 (2013.01); C07K 16/32 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 15 Claims
 
1. An antibody-albumin nanoparticle complex comprising albumin, a bevacizumab antibody, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro by mixing an aqueous albumin-paclitaxel nanoparticle with the antibody under conditions to form the nanoparticle complex, such that the nanoparticle complex has VEGF binding specificity, and wherein the complex has a diameter of between 0.1 μm and 1 μm.